Search the Newsreel

Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition

Repligen, a life sciences company based in Waltham, Massachusetts, is set to acquire Washington-based BioLife Solutions Inc. for $1.5 billion. The acquisition, a mix of cash and stock, aims to expand Repligen's capabilities in the cell therapy market by integrating BioLife Solutions' cell processing …

Replimune Group Reaches Analyst Target Price

In recent trading, shares of Replimune Group Inc (Symbol: REPL) have crossed above the average analyst 12-month target price of $10.67, changing hands for $11.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade …

Repligen to buy cell therapy maker BioLife in $1.5 billion deal

Repligen Corp announced it will acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal. This acquisition will expand Repligen's presence in the growing cell therapy market by gaining access to BioLife's cell-preservation technology and processing tools. The deal is expected to increase …

Repligen to acquire BioLife Solutions for $1.5 billion

Repligen Corporation has announced its acquisition of BioLife Solutions Inc. for approximately $1.5 billion in a cash and stock deal. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, totaling $31.00. The acquisition, expected to close in …

BioLife’s Biopreservation Media Supports 18 Commercially Approved Therapies

Repligen Corporation has announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to strengthen its position in the cell therapy market. BioLife stockholders will receive a mix of cash and Repligen stock, valued at $31.00 per share. The acquisition is …

Replimune stock gains after updated RP1 data and cash runway outlook

Replimune Group Inc. (REPL) stock is reacting to updated clinical data for its oncolytic immunotherapy RP1 and a strengthened cash position. The company reported $357 million in cash and short-term investments as of March 31, 2024, which management expects will fund operations into 2028. …

Why Repligen (RGEN) Stock Is Trading Lower Today

Repligen (RGEN) stock is trading lower after the biopharma manufacturing company provided weak full-year guidance ahead of its Q2 earnings report. This decline was exacerbated by concerns regarding project delays highlighted by industry peer Danaher, which also saw its shares fall due to similar …

Repligen (RGEN) Expected to Announce Quarterly Earnings on Tuesday

ETFs Investing in Replimune Group, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Replimune Group, Inc. (A2JQN1) stocks, offering investors diversified exposure to the company. The ETFs are sorted by their market value of Replimune holdings and include details such as issuer, management style, expense ratio, AUM, …

Repligen (RGEN) Q3 2025 earnings summary

Repligen (RGEN) reported strong Q3 2025 results with $189 million in revenue, a 22% year-over-year increase, driven by double-digit growth across all franchises and geographies. The company achieved a net income of $15 million and completed strategic acquisitions to strengthen its product lines. Repligen …

Form 4 Repligen Corporation For: 17 July By Investing.com

This article announces the filing of a Form 4 for Repligen Corporation related to July 17. The brief report from Investing.com indicates insider activity for the company, providing information relevant to investors tracking corporate disclosures.

Repligen CFO Jason K Garland sells $79,500 in stock

Repligen CFO Jason K Garland sold 530 shares of the company's common stock for $79,500 on July 16, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while REPLIGEN shares were trading at $147.25, with InvestingPro analysis suggesting the stock is …

Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN)

Jason Garland, the CFO of Repligen Corp's subsidiary, sold 530 shares of RGEN on July 16, 2026, and now owns 18,829 shares. Over the past year, Garland has sold 1,263 shares with no purchases, contributing to a total of 1 insider buy and 9 …

Repligen (NASDAQ: RGEN) CFO trades 530 shares in 10b5-1 plan sale

Repligen Corp's CFO, Jason K. Garland, reported selling 530 shares of common stock at $150.00 per share on July 16, 2026. This transaction was conducted under a Rule 10b5-1 trading plan, adopted on December 8, 2025. Following the sale, Garland directly holds 18,829 shares …

Issuer RGEN (NASDAQ: RGEN) plans 530-share sale by Form 144 filer

Jason K. Garland has filed a Form 144 notice to sell 530 common shares of Repligen Corporation (NASDAQ: RGEN) with an aggregate market value of $79,500.00. These shares were acquired through Restricted Stock Vesting on February 27, 2025, as compensation. The filing also reports …

RGEN5964422 Bond Risk Profile

This article provides an overview of the RGEN5964422 bond risk profile for Repligen Corporation's 1.0% bond due December 15, 2028. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating. The platform also offers access to exclusive analyst …

RGEN5964422 Bond Profile — Key Metrics

This article provides key metrics for the RGEN5964422 bond issued by Repligen Corporation. The bond has a 1.0% coupon rate and matures on December 15, 2028, with an outstanding amount of $600 million. Repligen Corp. is a global life sciences company founded in 1981, …

Liquidity Mapping Around (REPL) Price Events

This article analyzes Replimune Group Inc. (NASDAQ: REPL) stock, identifying weak near- and mid-term sentiment with a neutral long-term outlook. It highlights an exceptional risk-reward short setup and provides three AI-generated trading strategies tailored for different risk profiles: Position Trading, Momentum Breakout, and Risk …

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Replimune Group, Inc. (REPL) on behalf of long-term shareholders who held shares continuously since prior to November 22, 2024. The investigation stems from allegations that Replimune made misleading …

Repligen to report Q2 2026 financial results on July 28

Repligen Corporation is set to announce its second-quarter 2026 financial results on July 28, 2026, covering the period ended June 30, 2026. The company will issue a press release before market open, followed by a conference call at 8:00 a.m. ET to discuss the …

Repligen Schedules 8 a.m. ET Webcast for July 28 Results

Repligen (NASDAQ: RGEN) announced it will report its Q2 2026 financial results on Tuesday, July 28, 2026. A press release will be issued before market open, followed by a conference call and webcast at 8:00 a.m. ET to discuss business updates and results for …

REPLOID Group AG AKTIE • AT0000A3HRX5

Careplus Group Berhad (0163.KL) Stock Price, News, Quote & History